Lee, J. E., Nam, J. H., Kwon, S. H., Kim, B. K., & Ha, S. M. Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL). Wiley.
Chicago Style (17th ed.) CitationLee, Jeong Eun, Jin Hyun Nam, Sun Hong Kwon, Bo Kyung Kim, and Seung Min Ha. Real‐world Evidence of Brigatinib as Second‐line Treatment After Crizotinib for ALK+ Non‐small Cell Lung Cancer Using South Korean Claims Data (K‐AREAL). Wiley.
MLA (9th ed.) CitationLee, Jeong Eun, et al. Real‐world Evidence of Brigatinib as Second‐line Treatment After Crizotinib for ALK+ Non‐small Cell Lung Cancer Using South Korean Claims Data (K‐AREAL). Wiley.
Warning: These citations may not always be 100% accurate.